Clinical trials: RAS Wild Type
Colorectal Cancer Metastatic
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF…
- Trial name
- NCT06379399
- Testing
- Cetuximab, Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Wangxia LV
Colorectal Cancer, Drug Resistance
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
To evaluate the emergence of RAS mutation in patients with metastatic colorectal cancer, circulating free DNA will be analyzed using mass spectrometric genotyping in subjects during cetuximab treatment.
- Conditions
- Colorectal Cancer, Drug Resistance, Mass Spectrometry, RAS-RAF Pathway Deregulation
- Trial name
- NCT03401957
- Testing
- Cetuximab, liquid biopsy
- Where
- 4 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- National Health Research Institutes, Taiwan
Rectal Cancer
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
The study is a multicenter, open-label, phase II clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR)) of…
- Trial name
- NCT06542588
- Testing
- HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
- Where
- 3 sites in China
- Volunteers
- 29 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Colorectal Cancer
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
This is a phase II trial to examine the efficacy of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (all RAS/NRAS/BRAF/PIK3CA wild-type), metastatic colorectal cancer based on HER2…
- Trial name
- NCT03457896
- Testing
- Trastuzumab, Cetuximab, Neratinib
- Where
- 48 sites in United States
- Volunteers
- 35 people
- Sponsor
- NSABP Foundation Inc
Metastatic Colorectal Cancer
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
The primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously…
- Trial name
- CEIL (NCT05959356)
- Testing
- Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6
- Where
- 3 sites in China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type…
- Trial name
- PARADIGM (NCT02394795)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 155 sites in Japan
- Volunteers
- 823 people
- Sponsor
- Takeda
Colorectal Neoplasms
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
This study will assess the safety and anticancer activity of TQB2922 injection given under the skin together with chemotherapy in adults with colorectal cancer that has spread, cannot be removed by surgery, and has no RAS or BRAF…
- Trial name
- NCT07844187
- Testing
- TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium)
- Where
- 16 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that has spread to other places in the body…
- Conditions
- Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation
- Trial name
- NCT03317119
- Testing
- Laboratory Biomarker Analysis, Trametinib, Trifluridine and Tipiracil Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Non-Small-Cell Lung Cancer
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
The purpose of this multicenter, Phase II trial is to examine the role of a well-tolerated novel agent, panitumumab, in combination with a modern platinum doublet regimen using carboplatin and pemetrexed, in patients with…
- Trial name
- NCT01042288
- Testing
- Carboplatin, Pemetrexed, Panitumumab
- Where
- 13 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Colorectal Cancer
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer
To estimate the progression free survival for subjects treated with panitumumab in combination with a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX) as first-line chemotherapy regimen for…
- Trial name
- PULSE (NCT01288339)
- Testing
- Panitumumab + FOLFOX (DP), Panitumumab + FOLFOX (no-DP)
- Where
- 30 sites in Spain
- Volunteers
- 78 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer
Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer
This retrospective study, will evaluate patient outcomes after triplet chemotherapy (FOLFIRINOX) (5 Fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a RAS (KRAS, NRAS…
- Trial name
- ESTER (NCT03914170)
- Testing
- Folfirinox + cetuximab
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Advanced Colorectal Cancer
Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status
The study will a be a biologically enriched, prospectively stratified phase II trial in RAS wild type metastatic colorectal cancer patients progressing after first-line treatment with oxaliplatin, fluoropyrimidines and an…
- Trial name
- DISTINCTIVE (NCT04252456)
- Testing
- Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan
- Where
- 16 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal cancer that expresses the RAS and B-Raf…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02508077
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
The Nordic FLOX-regime consists of a combination of bolus 5-FU, leukovorin and oxaliplatin (Eloxatin®). Cetuximab (Erbitux®) is an antibody against the epidermal growth factor receptor (EGFR).
- Trial name
- NCT00660582
- Testing
- Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 152 people
- Sponsor
- Per Pfeiffer
Colorectal Cancer Metastatic
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab
Adenocarcinoma of the colon and rectum is a common, serious disease and it is the second cause of death from cancer in Spain. The prognosis of CRC depends to a great extent on its stage when diagnosed.
- Trial name
- BEAMING (NCT01943786)
- Testing
- FOLFIRI + Cetuximab
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Sofia Perea, Director Clinical Trials Unit.
Liver Metastasis, Colorectal Cancer
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined…
- Trial name
- ATOM ES (NCT01834014)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- EPS Corporation
Incurable Colorectal Cancer, RAS-wild-type
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
1. To evaluate efficacy, safety, and feasibility of maintenance therapy with Cetuximab combined with irinotecan or fluorouracil after Cetuximab plus irinotecan and fluorouracil(FOLFIRI) in patients with incurable colorectal…
- Trial name
- NCT02071069
- Testing
- Cetuximab, irinotecan, fluorouracil
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tianshu Liu
Advanced Colorectal Cancer
A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer
A study of Cetuximabβ combined with Envolimab and mFOLFOX6 in Subjects with Advanced Colorectal Cancer
- Trial name
- SUPβORT (NCT07000305)
- Testing
- Cetuximabβ combined with Envolimab and mFOLFOX6
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Tao Zhang
Cancer of Colon
Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
This research is intended to check the benefit of treatment with cetuximab in metastatic colorectal cancer patients with wild type RAS as third line treatment. The advantage to the patients is unclear.
- Trial name
- NCT03524820
- Testing
- Cetuximab
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Metastatic Colorectal Cancer
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR Monoclonal antibody（SCT200）in patients with wild-type RAS and BRAF mCRC treated with fluorouracil, oxaliplatin and irinotecan after failure…
- Trial name
- NCT03405272
- Testing
- Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
- Where
- 21 sites in China
- Volunteers
- 110 people
- Sponsor
- Sinocelltech Ltd.